Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
<h4>Objective</h4>To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.<h4>Methods</h4>An observational, retrospect...
Guardado en:
Autores principales: | J E Meca-Lallana, C Oreja-Guevara, D Muñoz, J Olascoaga, A Pato, L Ramió-Torrentà, V Meca-Lallana, M A Hernández, M E Marzo, J C Álvarez-Cermeño, A Rodríguez-Antigüedad, X Montalbán, O Fernández, Spanish GILENYA Registry Investigators |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/07987836f8b74fd78ad563e5d9b47c6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke C, et al.
Publicado: (2011) -
Neuroprotective Effects of Fingolimod in a Cellular Model of Optic Neuritis
por: Amritha A. Candadai, et al.
Publicado: (2021) -
Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire.
por: José E Meca-Lallana, et al.
Publicado: (2021) -
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
por: Jagadeswara Rao Earla, et al.
Publicado: (2021) -
Voluntad de poder e interpretación como supuestos de todo proceso orgánico
por: Sánchez Meca, Diego
Publicado: (2009)